Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

357 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.
Robinson JI, Md Yusof MY, Davies V, Wild D, Morgan M, Taylor JC, El-Sherbiny Y, Morris DL, Liu L, Rawstron AC, Buch MH, Plant D, Cordell HJ, Isaacs JD, Bruce IN, Emery P, Barton A, Vyse TJ, Barrett JH, Vital EM, Morgan AW; MATURA Consortia; MASTERPLANS Consortia. Robinson JI, et al. Among authors: bruce in. EBioMedicine. 2022 Dec;86:104343. doi: 10.1016/j.ebiom.2022.104343. Epub 2022 Nov 11. EBioMedicine. 2022. PMID: 36371989 Free PMC article.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
Petri M, Bruce IN, Dörner T, Tanaka Y, Morand EF, Kalunian KC, Cardiel MH, Silk ME, Dickson CL, Meszaros G, Zhang L, Jia B, Zhao Y, McVeigh CJ, Mosca M. Petri M, et al. Among authors: bruce in. Lancet. 2023 Mar 25;401(10381):1011-1019. doi: 10.1016/S0140-6736(22)02546-6. Epub 2023 Feb 24. Lancet. 2023. PMID: 36848919 Clinical Trial.
Correction: Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil.
Akthar M, Nair N, Carter LM, Vital EM, Sutton E, McHugh N; British Isles Lupus Assessment Group Biologics Register (BILAG BR) Consortium; MASTERPLANS Consortium; Bruce IN, Reynolds JA. Akthar M, et al. Among authors: bruce in. Arthritis Res Ther. 2023 Sep 4;25(1):160. doi: 10.1186/s13075-023-03160-1. Arthritis Res Ther. 2023. PMID: 37667347 Free PMC article. No abstract available.
Targeting DORIS Remission and LLDAS in SLE: A Review.
Parra Sánchez AR, van Vollenhoven RF, Morand EF, Bruce IN, Kandane-Rathnayake R, Weiss G, Tummala R, Al-Mossawi H, Sorrentino A. Parra Sánchez AR, et al. Among authors: bruce in. Rheumatol Ther. 2023 Dec;10(6):1459-1477. doi: 10.1007/s40744-023-00601-w. Epub 2023 Oct 5. Rheumatol Ther. 2023. PMID: 37798595 Free PMC article. Review.
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. Fanouriakis A, et al. Among authors: bruce in. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762. Ann Rheum Dis. 2024. PMID: 37827694
Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study.
Rodziewicz M, Dyball S, Lunt M, McDonald S, Sutton E, Parker B, Bruce IN; British Isles Lupus Assessment Group Biologics Register (BILAG-BR) consortium. Rodziewicz M, et al. Among authors: bruce in. Lancet Rheumatol. 2023 May;5(5):e284-e292. doi: 10.1016/S2665-9913(23)00091-7. Lancet Rheumatol. 2023. PMID: 38251591 Free article.
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Bruce IN, Nami A, Schwetje E, Pierson ME, Rouse T, Chia YL, Kuruvilla D, Abreu G, Tummala R, Lindholm C. Bruce IN, et al. Lancet Rheumatol. 2021 Feb;3(2):e101-e110. doi: 10.1016/S2665-9913(20)30342-8. Epub 2020 Nov 20. Lancet Rheumatol. 2021. PMID: 38279367
OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set.
Nielsen W, Strand V, Simon LS, Parodis I, Kim AHJ, Desai M, Enman Y, Wallace D, Chaichian Y, Navarra S, Aranow C, MacKay M, Trotter K, Tayer-Shifman OE, Duarte-Garcia A, Shan Tam L, Ugarte-Gil MF, PonsEstel GJ, Reynolds JA, Nikpour M, Hoi A, Romero-Diaz J, Papachristos D, Aggarwal A, Mok CC, Fujio K, Ramsey-Goldman R, Howe A, Kia BN, Bonilla D, Thumboo J, Mosca M, Aringer M, Johnson SR, Drucker AM, Morand E, Bruce I, Touma Z; OMERACT SLE Working Group. Nielsen W, et al. Semin Arthritis Rheum. 2024 Apr;65:152380. doi: 10.1016/j.semarthrit.2024.152380. Epub 2024 Jan 14. Semin Arthritis Rheum. 2024. PMID: 38281467
Correction: Targeting DORIS Remission and LLDAS in SLE: A Review.
Parra Sánchez AR, van Vollenhoven RF, Morand EF, Bruce IN, Kandane-Rathnayake R, Weiss G, Tummala R, Al-Mossawi H, Sorrentino A. Parra Sánchez AR, et al. Among authors: bruce in. Rheumatol Ther. 2024 Aug;11(4):1059-1061. doi: 10.1007/s40744-024-00679-w. Rheumatol Ther. 2024. PMID: 38847996 Free PMC article. No abstract available.
357 results